Fenwick Represents Scribe Therapeutics in $155.1M Upsized Public Offering

Fenwick represented Scribe Therapeutics (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, in its upsized initial public offering of 9,867,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 1,287,000 additional shares, at the initial public offering price of $15.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses were $155.1 million.

Leerink Partners, Goldman Sachs & Co. LLC, Guggenheim Securities and Wells Fargo Securities acted as joint book-running managers for the offering. More information can be obtained from Scribe’s announcement.

The Fenwick transaction team included corporate partners Rob Freedman, Ryan Mitteness and Effie Toshav and associates Adam Conway, Elsie Cheang, Lindsey Macalalad, Sarah Marshall, Guy Rotstein and Patrick Paulsen; and executive compensation and employee benefits partner Liz Gartland and associate Christophe Delrieu.